Does ixazomib need to be taken long-term to maintain the therapeutic effect?

Ixazomib is an oral proteasome inhibitor mainly used to treat multiple myeloma. As a targeted therapy drug, ixazomib inhibits the growth of tumors by inhibiting the proteasome function in tumor cells and promoting the apoptosis of malignant cells. Treatment with ixazomib is usually used in the maintenance treatment of multiple myeloma. Patients usually enter the maintenance treatment phase after induction therapy. The goal of treatment at this stage is to delay the recurrence of the disease.

Regarding the question of whether ixazomib needs to be taken long-term to maintain therapeutic effects, the answer is yes. Ixazomib is usually taken as part of long-term maintenance therapy to delay disease recurrence. Under current treatment regimens, ixazomib can be continued until the patient experiences disease recurrence or must discontinue treatment due to adverse effects. Its role in treatment is to help maintain disease remission and prevent the recurrence of multiple myeloma through long-term and sustained proteasome inhibition. Although some patients have stable efficacy during the maintenance treatment phase, in order to ensure long-term control of the disease, patients generally need to continue using ixazomib under the guidance of a doctor.

The treatment duration of ixazomib is usually adjusted based on the patient's disease response. In some patients, treatment can last for months or even years. However, long-term use of this medication may increase the risk of side effects, and patients will need to undergo regular clinical examinations to evaluate kidney function, blood counts, and other potential side effects. Therefore, as a maintenance treatment drug, ixazomib does need to be taken long-term to ensure that the therapeutic effect is maintained and the progression of the disease is delayed.

Reference materials:https://www.ninlaro.com/